This is a good article. Click here for more information.


From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Systematic (IUPAC) name
2-(acetoxy)benzoic acid
Clinical data
Pronunciation acetylsalicylic acid /əˌstəlˌsælˈsɪlk/
AHFS/ monograph
MedlinePlus a682878
  • AU: C
  • US: C (Risk not ruled out) D in the 3rd trimester
Legal status
  • AU: S2 (Pharmacy only) except when given intravenously (in which case it is schedule 4), used in animal medicine (schedule 5/6) or when the dose is higher than usual.
  • UK: General sales list (GSL, OTC)
  • US: OTC
Routes of
Most commonly oral, also rectal, lysine acetylsalicylate may be given intravenously or intramuscularly
Pharmacokinetic data
Bioavailability 80–100%[1]
Protein binding 80–90%[2]
Metabolism Hepatic, (CYP2C19 and possibly CYP3A), some is also hydrolysed to salicylate in the gut wall.[2]
Biological half-life Dose-dependent; 2–3 hours for low doses, 15–30 hours for large doses.[2]
Excretion Urine (80–100%), sweat, saliva, feces[1]
CAS Number 50-78-2 YesY
ATC code A01AD05 (WHO) B01AC06, N02BA01
PubChem CID: 2244
DrugBank DB00945 YesY
ChemSpider 2157 YesY
KEGG D00109 YesY
ChEBI CHEBI:15365 YesY
Synonyms 2-acetoxybenzoic acid
acetylsalicylic acid
O-acetylsalicylic acid
Chemical data
Formula C9H8O4
Molecular mass 180.157 g/mol
Physical data
Density 1.40 g/cm3
Melting point 135 °C (275 °F)
Boiling point 140 °C (284 °F) (decomposes)
Solubility in water 3 mg/mL (20 °C)

Aspirin, also known as acetylsalicylic acid (ASA), is a medication, often used to treat pain, fever, and inflammation.[2] Aspirin is also used long-term, at low doses, to help prevent heart attacks, strokes, and blood clot formation in people at high risk of developing blood clots.[3] Low doses of aspirin may be given immediately after a heart attack to reduce the risk of another heart attack or of the death of heart tissue.[4][5] Aspirin may be effective at preventing certain types of cancer, particularly colorectal cancer.[6][7][8]

The main side effects of aspirin are gastric ulcers, stomach bleeding, and ringing in the ears, especially with higher doses. While daily aspirin can help prevent a clot-related stroke, it may increase risk of a bleeding stroke (hemorrhagic stroke).[9] In children and adolescents, aspirin is not recommended for flu-like symptoms or viral illnesses, because of the risk of Reye's syndrome.[10]

Aspirin is part of a group of medications called nonsteroidal anti-inflammatory drugs (NSAIDs), but differs from most other NSAIDs in the mechanism of action. The salicylates have similar effects (antipyretic, anti-inflammatory, analgesic) to the other NSAIDs and inhibit the same enzyme cyclooxygenase (COX), but aspirin does so in an irreversible manner and, unlike others, affects the COX-1 variant more than the COX-2 variant of the enzyme.[11] Aspirin also has an antiplatelet effect by stopping the binding together of platelets.

The therapeutic properties of willow tree bark have been known for at least 2,400 years, with Hippocrates prescribing it for headaches.[12] Salicylic acid, the active ingredient of aspirin, was first isolated from the bark of the willow tree in 1763 by Edward Stone of Wadham College, University of Oxford.[13] Felix Hoffmann, a chemist at Bayer, is credited with the synthesis of aspirin in 1897, though whether this was of his own initiative or under the direction of Arthur Eichengrün is controversial.[14][15] Aspirin is one of the most widely used medications in the world with an estimated 40,000 tonnes of it being consumed each year.[16] In countries where "Aspirin" is a registered trademark owned by Bayer, the generic term is acetylsalicylic acid (ASA).[17] It is on the WHO Model List of Essential Medicines, the most important medications needed in a basic health system.[18]

Medical use

Aspirin is used in the treatment of a number of conditions, including fever, pain, rheumatic fever, and inflammatory diseases, such as rheumatoid arthritis, pericarditis, and Kawasaki disease.[19] Lower doses of aspirin have also shown to reduce the risk of death from a heart attack, or the risk of stroke in some circumstances.[20][21][22] There is some evidence that aspirin is effective at preventing colorectal cancer, though the mechanisms of this effect are unclear.[23]


Aspirin 325 mg / 5 grains for pain
Uncoated aspirin tablets, consisting of about 90% acetylsalicylic acid, along with a minor amount of inert fillers and binders

Aspirin is an effective analgesic for acute pain, but is generally considered inferior to ibuprofen for the alleviation of pain because aspirin is more likely to cause gastrointestinal bleeding.[24] Aspirin is generally ineffective for those pains caused by muscle cramps, bloating, gastric distension, or acute skin irritation.[25] As with other NSAIDs, combinations of aspirin and caffeine provide slightly greater pain relief than aspirin alone.[26] Effervescent formulations of aspirin, such as Alka-Seltzer or Blowfish,[27] relieve pain faster than aspirin in tablets,[28] which makes them useful for the treatment of migraines.[29] Topical aspirin may be effective for treating some types of neuropathic pain.[30]


Aspirin, either by itself or in a combined formulation, effectively treats some types of headache, but its efficacy may be questionable for others. Secondary headaches, meaning those caused by another disorder or trauma, should be promptly treated by a medical provider.

Among primary headaches, the International Classification of Headache Disorders distinguishes between tension headache (the most common), migraine, and cluster headache. Aspirin or other over-the-counter analgesics are widely recognized as effective for the treatment of tension headache.[31]

Aspirin, especially as a component of an acetaminophen/aspirin/caffeine, is considered a first-line therapy in the treatment of migraine, and comparable to lower doses of sumatriptan. It is most effective at stopping migraines when they are first beginning.[32]


Like its ability to control pain, aspirin's ability to control fever is due to its action on the prostaglandin system through its irreversible inhibition of COX.[33] Although aspirin's use as an antipyretic in adults is well-established, many medical societies and regulatory agencies (including the American Academy of Family Physicians, the American Academy of Pediatrics, and the U.S. Food and Drug Administration (FDA)) strongly advise against using aspirin for treatment of fever in children because of the risk of Reye's syndrome, a rare but often fatal illness associated with the use of aspirin or other salicylates in children during episodes of viral or bacterial infection.[34][35][36] Because of the risk of Reye's syndrome in children, in 1986, the FDA required labeling on all aspirin-containing medications advising against its use in children and teenagers.[37]


Aspirin is used as an anti-inflammatory agent for both acute and long-term inflammation,[38] as well as for treatment of inflammatory diseases, such as rheumatoid arthritis.[19]

Heart attacks and strokes

Aspirin is an important part of the treatment of those who have had a myocardial infarction (heart attack).[39] One trial found that among those likely having a ST-segment elevation MI, aspirin saves the life of 1 in 42 by reducing the 30-day death rate from 11.8% to 9.4%.[40] There was no difference in major bleeding, but there was a small increase in minor bleeding amounting to roughly 1 in every 167 people given aspirin.[40]

High risk

For people who have already had a heart attack or stroke, taking aspirin daily for two years prevented 1 in 50 from having a cardiovascular problem (heart attack, stroke, or death), but also caused non-fatal bleeding problems to occur in 1 of 400 people.[41][42][43]

Lower risk

Studies have not found an overall benefit in the general population of healthy people, although it is possible that there are small benefits for those at especially high risk, despite never having had a heart attack or stroke in the past.[44] One study found that among those who have never had a heart attack or stroke, taking aspirin daily for 1 year prevents 1 in 1,667 from having a non-fatal heart attack or stroke, but caused 1 in 3,333 to have a non-fatal bleeding event. However, the people looked at were at relatively higher risk than most people who have never had a heart attack or stroke.[45]

Aspirin appears to offer little benefit to those at lower risk of heart attack or stroke—for instance, those without a history of these events or with pre-existing disease. Some studies recommend aspirin on a case-by-case basis,[46][47] while others have suggested the risks of other events, such as gastrointestinal bleeding, were enough to outweigh any potential benefit, and recommended against using aspirin for primary prevention entirely.[48] Aspirin has also been suggested as a component of a polypill for prevention of cardiovascular disease.[49][50]

Complicating the use of aspirin for prevention is the phenomenon of aspirin resistance.[51][52] For people who are resistant, aspirin's efficacy is reduced.[53] Some authors have suggested testing regimens to identify people who are resistant to aspirin.[54]

After surgery

After percutaneous coronary interventions (PCIs), such as the placement of a coronary artery stent, a U.S. Agency for Healthcare Research and Quality guideline recommends that aspirin be taken indefinitely.[55] Frequently, aspirin is combined with an ADP receptor inhibitor, such as clopidogrel, prasugrel, or ticagrelor to prevent blood clots. This is called dual antiplatelet therapy (DAPT). United States and European Union guidelines disagree somewhat about how long, and for what indications this combined therapy should be continued after surgery. U.S. guidelines recommend DAPT for at least 12 months, while EU guidelines recommend DAPT for 6–12 months after a drug-eluting stent placement.[56] However, they agree that aspirin be continued indefinitely after DAPT is complete.

Cancer prevention

Aspirin reduces the overall risk of both getting cancer and dying from cancer.[57] This effect is particularly beneficial for colorectal cancer (CRC).[23][58][59][60]

Some conclude the benefits are greater than the risks due to bleeding in those at average risk.[57] Other are unclear if the benefits are greater than the risk.[61][62] Given this uncertainty, the 2007 United States Preventive Services Task Force guidelines on this topic recommended against the use of aspirin for prevention of CRC in people with average risk.[63]

Other uses

Aspirin is a first-line treatment for the fever and joint-pain symptoms of acute rheumatic fever. The therapy often lasts for one to two weeks, and is rarely indicated for longer periods. After fever and pain have subsided, the aspirin is no longer necessary, since it does not decrease the incidence of heart complications and residual rheumatic heart disease.[64][65] Naproxen has been shown to be as effective as aspirin and less toxic, but due to the limited clinical experience, naproxen is recommended only as a second-line treatment.[64][66]

Along with rheumatic fever, Kawasaki disease remains one of the few indications for aspirin use in children[67] in spite of a lack of high quality evidence for its effectiveness.[68]

Low-dose aspirin supplementation has moderate benefits when used for prevention of pre-eclampsia.[69][70]


For some people, aspirin does not have as strong an effect on platelets as for others, an effect known as aspirin resistance or insensitivity. One study has suggested women are more likely to be resistant than men,[71] and a different, aggregate study of 2,930 patients found 28% were resistant.[72] A study in 100 Italian patients, though, found, of the apparent 31% aspirin-resistant subjects, only 5% were truly resistant, and the others were noncompliant.[73] Another study of 400 healthy volunteers found no subjects who were truly resistant, but some had "pseudoresistance, reflecting delayed and reduced drug absorption".[74]


Coated 325-mg (5-grain) aspirin tablets
The 5-grain aspirin. The usage guidance label on a bottle of aspirin indicates that the dosage is "325 mg (5 gr)".

Adult aspirin tablets are produced in standardised sizes, which vary slightly from country to country, for example 300 mg in Britain and 325 mg (or 5 grains) in the United States. Smaller doses are based on these standards, e.g., 75-mg and 81-mg tablets. The 81-mg (1​14-grain) tablets are commonly called "baby aspirin" or "baby-strength", because they were originally—but no longer—intended to be administered to infants and children.[75] No medical significance occurs due to the slight difference in dosage between the 75-mg and the 81-mg tablets.

In general, for adults, doses are taken four times a day for fever or arthritis,[76] with doses near the maximal daily dose used historically for the treatment of rheumatic fever.[77] For the prevention of myocardial infarction (MI) in someone with documented or suspected coronary artery disease, much lower doses are taken once daily.[76]

Recommendations from the USPSTF[78] on the use of aspirin for the primary prevention of coronary heart disease encourage men aged 45–79 and women aged 55–79 to use aspirin when the potential benefit of a reduction in MI for men or stroke for women outweighs the potential harm of an increase in gastrointestinal hemorrhage.[79] The WHI study said regular low-dose (75- or 81-mg) aspirin female users had a 25% lower risk of death from cardiovascular disease and a 14% lower risk of death from any cause.[79] Low-dose aspirin use was also associated with a trend toward lower risk of cardiovascular events, and lower aspirin doses (75 or 81 mg/day) may optimize efficacy and safety for patients requiring aspirin for long-term prevention.[79]

In children with Kawasaki disease, aspirin is taken at dosages based on body weight, initially four times a day for up to two weeks and then at a lower dose once daily for a further six to eight weeks.[80]

Adverse effects


Aspirin should not be taken by people who are allergic to ibuprofen or naproxen,[81][82] or who have salicylate intolerance[83][84] or a more generalized drug intolerance to NSAIDs, and caution should be exercised in those with asthma or NSAID-precipitated bronchospasm. Owing to its effect on the stomach lining, manufacturers recommend people with peptic ulcers, mild diabetes, or gastritis seek medical advice before using aspirin.[81][85] Even if none of these conditions is present, the risk of stomach bleeding is still increased when aspirin is taken with alcohol or warfarin.[81][82] Patients with hemophilia or other bleeding tendencies should not take aspirin or other salicylates.[81][85] Aspirin is known to cause hemolytic anemia in people who have the genetic disease glucose-6-phosphate dehydrogenase deficiency, particularly in large doses and depending on the severity of the disease.[86] Use of aspirin during dengue fever is not recommended owing to increased bleeding tendency.[87] People with kidney disease, hyperuricemia, or gout should not take aspirin because it inhibits the kidneys' ability to excrete uric acid, thus may exacerbate these conditions. Aspirin should not be given to children or adolescents to control cold or influenza symptoms, as this has been linked with Reye's syndrome.[10]


Aspirin use has been shown to increase the risk of gastrointestinal bleeding.[88] Although some enteric-coated formulations of aspirin are advertised as being "gentle to the stomach", in one study, enteric coating did not seem to reduce this risk.[88] Combining aspirin with other NSAIDs has also been shown to further increase this risk.[88] Using aspirin in combination with clopidogrel or warfarin also increases the risk of upper gastrointestinal bleeding.[89]

Blockade of COX-1 by aspirin apparently results in the upregulation of COX-2 as part of a gastric defense[90] and that taking COX-2 inhibitors concurrently with aspirin increases the gastric mucosal erosion.[91] Therefore, caution should be exercised if combining aspirin with any "natural" supplements with COX-2-inhibiting properties, such as garlic extracts, curcumin, bilberry, pine bark, ginkgo, fish oil, resveratrol, genistein, quercetin, resorcinol, and others.

In addition to enteric coating, "buffering" is the other main method companies have used to try to mitigate the problem of gastrointestinal bleeding. Buffering agents are intended to work by preventing the aspirin from concentrating in the walls of the stomach, although the benefits of buffered aspirin are disputed. Almost any buffering agent used in antacids can be used; Bufferin, for example, uses magnesium oxide. Other preparations use calcium carbonate.[92]

Taking it with vitamin C is a more recently investigated method of protecting the stomach lining. Taking equal doses of vitamin C and aspirin may decrease the amount of stomach damage that occurs compared to taking aspirin alone.[93][94]

Central effects

Large doses of salicylate, a metabolite of aspirin, cause temporary tinnitus (ringing in the ears) based on experiments in rats, via the action on arachidonic acid and NMDA receptors cascade.[95]

Reye's syndrome

Reye's syndrome, a rare but severe illness characterized by acute encephalopathy and fatty liver, can occur when children or adolescents are given aspirin for a fever or other illnesses or infections. From 1981 through 1997, 1207 cases of Reye's syndrome in under-18 patients were reported to the U.S. Centers for Disease Control and Prevention. Of these, 93% reported being ill in the three weeks preceding onset of Reye's syndrome, most commonly with a respiratory infection, chickenpox, or diarrhea. Salicylates were detectable in 81.9% of children for whom test results were reported.[96] After the association between Reye's syndrome and aspirin was reported, and safety measures to prevent it (including a Surgeon General's warning, and changes to the labeling of aspirin-containing drugs) were implemented, aspirin taken by children declined considerably in the United States, as did the number of reported cases of Reye's syndrome; a similar decline was found in the United Kingdom after warnings against pediatric aspirin use were issued.[96] The U.S. Food and Drug Administration now recommends aspirin (or aspirin-containing products) should not be given to anyone under the age of 12 who has a fever,[10] and the British Medicines and Healthcare products Regulatory Agency recommends children who are under 16 years of age should not take aspirin, unless it is on the advice of a doctor.[97]


For a small number of people, taking aspirin can result in symptoms resembling an allergic reaction, including hives, swelling, and headache. The reaction is caused by salicylate intolerance and is not a true allergy, but rather an inability to metabolize even small amounts of aspirin, resulting in an overdose.

Aspirin and other NSAIDs, such as ibuprofen, may delay the healing of skin wounds.[98] Aspirin may however help heal venous leg ulcer that have not healed following usual treatment.[99]

Other adverse effects

Aspirin can induce swelling of skin tissues in some people. In one study, angioedema appeared one to six hours after ingesting aspirin in some of the patients. However, when the aspirin was taken alone, it did not cause angioedema in these patients; the aspirin had been taken in combination with another NSAID-induced drug when angioedema appeared.[100]

Aspirin causes an increased risk of cerebral microbleeds having the appearance on MRI scans of 5 to 10 mm or smaller, hypointense (dark holes) patches.[101][102] Such cerebral microbleeds are important, since they often occur prior to ischemic stroke or intracerebral hemorrhage, Binswanger disease, and Alzheimer's disease.[original research?]

A study of a group with a mean dosage of aspirin of 270 mg per day estimated an average absolute risk increase in intracerebral hemorrhage (ICH) of 12 events per 10,000 persons.[103] In comparison, the estimated absolute risk reduction in myocardial infarction was 137 events per 10,000 persons, and a reduction of 39 events per 10,000 persons in ischemic stroke.[103] In cases where ICH already has occurred, aspirin use results in higher mortality, with a dose of about 250 mg per day resulting in a relative risk of death within three months after the ICH around 2.5 (95% confidence interval 1.3 to 4.6).[104]

Aspirin and other NSAIDs can cause hyperkalemia by inducing a hyporeninemic hypoaldosteronic state via inhibition of prostaglandin synthesis; however, these agents do not typically cause hyperkalemia by themselves in the setting of normal renal function and euvolemic state.[105]

Aspirin can cause prolonged bleeding after operations for up to 10 days. In one study, 30 of 6499 elective surgical patients required reoperations to control bleeding. Twenty had diffuse bleeding and 10 had bleeding from a site. Diffuse, but not discrete, bleeding was associated with the preoperative use of aspirin alone or in combination with other NSAIDS in 19 of the 20 diffuse bleeding patients.[106]

On 9 July 2015, the FDA toughened warnings of increased heart attack and stroke risk associated with nonsteroidal anti-inflammatory drugs (NSAID). Aspirin is an NSAID but is not affected by the new warnings.[107]

Template:Bleeding worksheet


Aspirin overdose can be acute or chronic. In acute poisoning, a single large dose is taken; in chronic poisoning, higher than normal doses are taken over a period of time. Acute overdose has a mortality rate of 2%. Chronic overdose is more commonly lethal, with a mortality rate of 25%;[108] chronic overdose may be especially severe in children.[109] Toxicity is managed with a number of potential treatments, including activated charcoal, intravenous dextrose and normal saline, sodium bicarbonate, and dialysis.[110] The diagnosis of poisoning usually involves measurement of plasma salicylate, the active metabolite of aspirin, by automated spectrophotometric methods. Plasma salicylate levels in general range from 30–100 mg/l after usual therapeutic doses, 50–300 mg/l in patients taking high doses and 700–1400 mg/l following acute overdose. Salicylate is also produced as a result of exposure to bismuth subsalicylate, methyl salicylate, and sodium salicylate.[111][112]


Aspirin is known to interact with other drugs. For example, acetazolamide and ammonium chloride are known to enhance the intoxicating effect of salicylates, and alcohol, and also increases the gastrointestinal bleeding associated with these types of drugs.[81][82] Aspirin is known to displace a number of drugs from protein-binding sites in the blood, including the antidiabetic drugs tolbutamide and chlorpropamide, warfarin, methotrexate, phenytoin, probenecid, valproic acid (as well as interfering with beta oxidation, an important part of valproate metabolism), and other NSAIDs. Corticosteroids may also reduce the concentration of aspirin. Ibuprofen can negate the antiplatelet effect of aspirin used for cardioprotection and stroke prevention.[113] The pharmacological activity of spironolactone may be reduced by taking aspirin, and it is known to compete with penicillin G for renal tubular secretion.[114] Aspirin may also inhibit the absorption of vitamin C.[115][116][117]

Chemical properties

Aspirin decomposes rapidly in solutions of ammonium acetate or of the acetates, carbonates, citrates, or hydroxides of the alkali metals. It is stable in dry air, but gradually hydrolyses in contact with moisture to acetic and salicylic acids. In solution with alkalis, the hydrolysis proceeds rapidly and the clear solutions formed may consist entirely of acetate and salicylate.[118]

Like flour mills, factories that make aspirin tablets must pay attention to how much of the powder gets into the air inside the building, because the powder-air mixture can be explosive. The National Institute for Occupational Safety and Health (NIOSH) has set a recommended exposure limit in the United States of 5 mg/m3 (time-weighted average).[119] In 1989, OSHA set a legal permissible exposure limit for aspirin of 5 mg/m3, but this was vacated by the AFL-CIO v. OSHA decision in 1993.[120]

Physical properties

Aspirin, an acetyl derivative of salicylic acid, is a white, crystalline, weakly acidic substance, with a melting point of 136 °C (277 °F), and a boiling point of 140 °C (284 °F).[121] Its acid dissociation constant (pKa) is 3.5 at 25 °C (77 °F).[122]


The synthesis of aspirin is classified as an esterification reaction. Salicylic acid is treated with acetic anhydride, an acid derivative, causing a chemical reaction that turns salicylic acid's hydroxyl group into an ester group (R-OH → R-OCOCH3). This process yields aspirin and acetic acid, which is considered a byproduct of this reaction. Small amounts of sulfuric acid (and occasionally phosphoric acid) are almost always used as a catalyst. This method is commonly employed in undergraduate teaching labs.[123]

Aspirin synthesis.png
Reaction mechanism
Acetylation of salicylic acid, mechanism

Formulations containing high concentrations of aspirin often smell like vinegar[124] because aspirin can decompose through hydrolysis in moist conditions, yielding salicylic and acetic acids.[125]


Polymorphism, or the ability of a substance to form more than one crystal structure, is important in the development of pharmaceutical ingredients. Many drugs are receiving regulatory approval for only a single crystal form or polymorph. For a long time, only one crystal structure for aspirin was known. That aspirin might have a second crystalline form was suspected since the 1960s. The elusive second polymorph was first discovered by Vishweshwar and coworkers in 2005,[126] and fine structural details were given by Bond et al.[127] A new crystal type was found after attempted cocrystallization of aspirin and levetiracetam from hot acetonitrile. The form II is only stable at 100 K and reverts to form I at ambient temperature. In the (unambiguous) form I, two salicylic molecules form centrosymmetric dimers through the acetyl groups with the (acidic) methyl proton to carbonyl hydrogen bonds, and in the newly claimed form II, each salicylic molecule forms the same hydrogen bonds with two neighboring molecules instead of one. With respect to the hydrogen bonds formed by the carboxylic acid groups, both polymorphs form identical dimer structures.[citation needed]

Mechanism of action

Discovery of the mechanism

In 1971, British pharmacologist John Robert Vane, then employed by the Royal College of Surgeons in London, showed aspirin suppressed the production of prostaglandins and thromboxanes.[128][129] For this discovery he was awarded the 1982 Nobel Prize in Physiology or Medicine, jointly with Sune K. Bergström and Bengt I. Samuelsson.[130] In 1984, he was made a Knight Bachelor.

Suppression of prostaglandins and thromboxanes

Aspirin's ability to suppress the production of prostaglandins and thromboxanes is due to its irreversible inactivation of the cyclooxygenase (COX; officially known as prostaglandin-endoperoxide synthase, PTGS) enzyme required for prostaglandin and thromboxane synthesis. Aspirin acts as an acetylating agent where an acetyl group is covalently attached to a serine residue in the active site of the PTGS enzyme. This makes aspirin different from other NSAIDs (such as diclofenac and ibuprofen), which are reversible inhibitors.

Low-dose aspirin use irreversibly blocks the formation of thromboxane A2 in platelets, producing an inhibitory effect on platelet aggregation during the lifetime of the affected platelet (8–9 days). This antithrombotic property makes aspirin useful for reducing the incidence of heart attacks.[131] 40 mg of aspirin a day is able to inhibit a large proportion of maximum thromboxane A2 release provoked acutely, with the prostaglandin I2 synthesis being little affected; however, higher doses of aspirin are required to attain further inhibition.[132]

Prostaglandins, local hormones produced in the body, have diverse effects, including the transmission of pain information to the brain, modulation of the hypothalamic thermostat, and inflammation. Thromboxanes are responsible for the aggregation of platelets that form blood clots. Heart attacks are caused primarily by blood clots, and low doses of aspirin are seen as an effective medical intervention for acute myocardial infarction.

COX-1 and COX-2 inhibition

At least two different types of cyclooxygenase occur: COX-1 and COX-2. Aspirin irreversibly inhibits COX-1 and modifies the enzymatic activity of COX-2. COX-2 normally produces prostanoids, most of which are proinflammatory. Aspirin-modified PTGS2 produces lipoxins, most of which are anti-inflammatory.[133] Newer NSAID drugs, COX-2 inhibitors (coxibs), have been developed to inhibit only PTGS2, with the intent to reduce the incidence of gastrointestinal side effects.[16]

However, several of the new COX-2 inhibitors, such as rofecoxib (Vioxx), have been withdrawn in the last decade, after evidence emerged that PTGS2 inhibitors increase the risk of heart attack and stroke.[134][135] Endothelial cells lining the microvasculature in the body are proposed to express PTGS2, and, by selectively inhibiting PTGS2, prostaglandin production (specifically, PGI2; prostacyclin) is downregulated with respect to thromboxane levels, as PTGS1 in platelets is unaffected. Thus, the protective anticoagulative effect of PGI2 is removed, increasing the risk of thrombus and associated heart attacks and other circulatory problems. Since platelets have no DNA, they are unable to synthesize new PTGS once aspirin has irreversibly inhibited the enzyme, an important difference with reversible inhibitors.

Additional mechanisms

Aspirin has been shown to have at least three additional modes of action. It uncouples oxidative phosphorylation in cartilaginous (and hepatic) mitochondria, by diffusing from the inner membrane space as a proton carrier back into the mitochondrial matrix, where it ionizes once again to release protons.[136] In short, aspirin buffers and transports the protons. When high doses of aspirin are given, it may actually cause fever, owing to the heat released from the electron transport chain, as opposed to the antipyretic action of aspirin seen with lower doses. In addition, aspirin induces the formation of NO-radicals in the body, which have been shown in mice to have an independent mechanism of reducing inflammation. This reduced leukocyte adhesion, which is an important step in immune response to infection; however, evidence is insufficient to show aspirin helps to fight infection.[137] More recent data also suggest salicylic acid and its derivatives modulate signaling through NF-κB.[138] NF-κB, a transcription factor complex, plays a central role in many biological processes, including inflammation.

Aspirin is readily broken down in the body to salicylic acid, which itself has anti-inflammatory, antipyretic, and analgesic effects. In 2012, salicylic acid was found to activate AMP-activated protein kinase, which has been suggested as a possible explanation for some of the effects of both salicylic acid and aspirin.[139][140] The acetyl portion of the aspirin molecule has its own targets. Acetylation of cellular proteins is a well-established phenomenon in the regulation of protein function at the post-translational level. Aspirin is able to acetylate several other targets in addition to COX isoenzymes.[141][142] These acetylation reactions may explain many hitherto unexplained effects of aspirin.


Acetylsalicylic acid is a weak acid, and very little of it is ionized in the stomach after oral administration. Acetylsalicylic acid is quickly absorbed through cell membrane in the acidic conditions of the stomach. The increased pH and larger surface area of the small intestine causes aspirin to be absorbed more slowly there, as more of it is ionised. Owing to the formation of concretions, aspirin is absorbed much more slowly during overdose, and plasma concentrations can continue to rise for up to 24 hours after ingestion.[143][144][145]

About 50–80% of salicylate in the blood is bound to albumin protein, while the rest remains in the active, ionized state; protein binding is concentration-dependent. Saturation of binding sites leads to more free salicylate and increased toxicity. The volume of distribution is 0.1–0.2 l/kg. Acidosis increases the volume of distribution because of enhancement of tissue penetration of salicylates.[145]

As much as 80% of therapeutic doses of salicylic acid is metabolized in the liver. Conjugation with glycine forms salicyluric acid, and with glucuronic acid to form two different gluconuride esters. The conjugate with the acetyl group intact is referred to as the acyl gluconuride; the deacetylated conjugate is the phenolic gluconuride. These metabolic pathways have only a limited capacity. Small amounts of salicylic acid are also hydroxylated to gentisic acid. With large salicylate doses, the kinetics switch from first-order to zero-order, as metabolic pathways become saturated and renal excretion becomes increasingly important.[145]

Salicylates are excreted mainly by the kidneys as salicyluric acid (75%), free salicylic acid (10%), salicylic phenol (10%), and acyl glucuronides (5%), gentisic acid (< 1%), and 2,3-dihydroxybenzoic acid.[146] When small doses (less than 250 mg in an adult) are ingested, all pathways proceed by first-order kinetics, with an elimination half-life of about 2.0 to 4.5 hours.[147][148] When higher doses of salicylate are ingested (more than 4 g), the half-life becomes much longer (15–30 hours),[149] because the biotransformation pathways concerned with the formation of salicyluric acid and salicyl phenolic glucuronide become saturated.[150] Renal excretion of salicylic acid becomes increasingly important as the metabolic pathways become saturated, because it is extremely sensitive to changes in urinary pH. A 10- to 20-fold increase in renal clearance occurs when urine pH is increased from 5 to 8. The use of urinary alkalinization exploits this particular aspect of salicylate elimination.[151]


1923 advertisement

Plant extracts, including willow bark and spiraea, of which salicylic acid was the active constituent, had been known to help alleviate headaches, pains, and fevers since antiquity. The father of modern medicine, Hippocrates (circa 460 – 377 BC), left historical records describing the use of powder made from the bark and leaves of the willow tree to help these symptoms.[152]

In 1763, Edward Stone, at Oxford, isolated the active ingredient of aspirin in his discovery of salicylic acid. A French chemist, Charles Frederic Gerhardt, was the first to prepare acetylsalicylic acid in 1853. In the course of his work on the synthesis and properties of various acid anhydrides, he mixed acetyl chloride with a sodium salt of salicylic acid (sodium salicylate). A vigorous reaction ensued, and the resulting melt soon solidified.[153] Since no structural theory existed at that time, Gerhardt called the compound he obtained "salicylic-acetic anhydride" (wasserfreie Salicylsäure-Essigsäure). This preparation of aspirin ("salicylic-acetic anhydride") was one of the many reactions Gerhardt conducted for his paper on anhydrides and he did not pursue it further.

Advertisement for Aspirin, Heroin, Lycetol, and Salophen

Six years later, in 1859, von Gilm obtained analytically pure acetylsalicylic acid (which he called acetylierte Salicylsäure, acetylated salicylic acid) by a reaction of salicylic acid and acetyl chloride.[154] In 1869, Schröder, Prinzhorn, and Kraut repeated both Gerhardt's (from sodium salicylate) and von Gilm's (from salicylic acid) syntheses and concluded both reactions gave the same compound—acetylsalicylic acid. They were first to assign to it the correct structure with the acetyl group connected to the phenolic oxygen.[155]

In 1897, chemists working at Bayer AG produced a synthetically altered version of salicin, derived from the species Filipendula ulmaria (meadowsweet), which caused less digestive upset than pure salicylic acid. The identity of the lead chemist on this project is a matter of controversy. Bayer states the work was done by Felix Hoffmann, but the Jewish chemist Arthur Eichengrün later claimed he was the lead investigator and records of his contribution were expunged under the Nazi regime.[14][156] The new drug, formally acetylsalicylic acid, was named Aspirin by Bayer AG after the original botanical name for meadowsweet, Spiraea ulmaria, derived from "acetyl" and Spirsäure, an old German name for salicylic acid derived from the Latin Spiraea ulmaria.[157] By 1899, Bayer was selling it around the world.[158] The popularity of aspirin grew over the first half of the 20th century, spurred by its supposed effectiveness in the wake of the Spanish flu pandemic of 1918. However, recent research suggests that the high death toll of the 1918 flu may have been partly due to aspirin, though this is controversial and not universally accepted.[159] This theory gained support when a recent repetition of the 1918 flu outbreak, with the same virus, had a low fatality rate. Aspirin's profitability led to fierce competition and the proliferation of aspirin brands and products, especially after the American patent held by Bayer expired in 1917.[160][161]

The popularity of aspirin declined after the market releases of paracetamol (acetaminophen) in 1956 and ibuprofen in 1969.[162] In the 1960s and 1970s, John Vane and others discovered the basic mechanism of aspirin's effects, while clinical trials and other studies from the 1960s to the 1980s established aspirin's efficacy as an anticlotting agent that reduces the risk of clotting diseases.[163] Aspirin sales revived considerably in the last decades of the 20th century, and remain strong in the 21st century, because of its widespread use as a preventive treatment for heart attacks and strokes.[164]

The first studies of the effect of aspirin on cardiac function and stroke prevention was carried out by Professor Peter Sleight,[165] Emeritus Professor of Cardiovascular Medicine at Oxford University, in the early 1970s.[166] Sleight and his research team at Oxford led the way and formed the foundation for the research into the use of aspirin in the prevention of other medical conditions.


Due to allowing the use of "Aspirin" for years by other manufacturing chemists, despite the patent-infringing nature of the use, and its own failure to use the name for its own product when it began selling direct, Bayer lost its trademark in 1918, affirmed by court appeal in 1921.[167] Today, aspirin is a generic word in Australia, France, India, Ireland, New Zealand, Pakistan, Jamaica, Colombia, the Philippines, South Africa, Ghana, the United Kingdom and the United States.[168] Aspirin, with a capital "A", remains a registered trademark of Bayer in Germany, Canada, Mexico, and in over 80 other countries, where the trademark is owned by Bayer, using acetylsalicylic acid in all markets, but using different packaging and physical aspects for each.[169][170]

Aspirin is the BAN and USAN.

Compendial status

Veterinary use

Aspirin is sometimes used for pain relief or as an anticoagulant in veterinary medicine, primarily in dogs and sometimes horses, although newer medications with fewer side effects are generally used instead.

Both dogs and horses are susceptible to the gastrointestinal side effects associated with salicylates, but it is a convenient treatment for arthritis in older dogs, and has shown some promise in cases of laminitis in horses.[173][174] It is no longer commonly used for cases of laminitis, as it could be counterproductive for treatment. Aspirin should be used in animals only under the direct supervision of a veterinarian; in particular, cats lack the glucuronide conjugates that aid in the excretion of aspirin, making it potentially toxic.[175] No clinical signs of toxicosis occurred when cats were given 25 mg/kg of aspirin every 48 hours for 4 weeks.[176] The dose recommended in cats for relief of pain and fever is 10 mg/kg every 48 hours.[177]


  1. 1.0 1.1 "Zorprin, Bayer Buffered Aspirin (aspirin) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 3 April 2014.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  2. 2.0 2.1 2.2 2.3 Brayfield, A, ed. (14 January 2014). "Aspirin". Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 3 April 2014.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  3. Lewis, H. D.; Davis, J. W.; Archibald, D. G.; Steinke, W. E.; Smitherman, T. C.; Doherty Je, J. E.; Schnaper, H. W.; Lewinter, M. M.; Linares, E.; Pouget, J. M.; Sabharwal, S. C.; Chesler, E.; Demots, H. (1983). "Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable Angina". New England Journal of Medicine. 309 (7): 396–403. doi:10.1056/NEJM198308183090703. PMID 6135989.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  4. Julian, D G; D A Chamberlain; S J Pocock (24 September 1996). "A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial". BMJ. British Medical Journal. 313 (7070): 1429–1431. doi:10.1136/bmj.313.7070.1429. PMC 2353012. PMID 8973228.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  5. Krumholz, H. M.; Radford, M. J.; Ellerbeck, E. F.; Hennen, J.; Meehan, T. P.; Petrillo, M.; Wang, Y.; Kresowik, T. F.; Jencks, S. F. (1995). "Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries. Patterns of use and outcomes". Circulation. 92 (10): 2841–2847. doi:10.1161/01.CIR.92.10.2841. PMID 7586250.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  6. Algra, Annemijn M; Rothwell, Peter M (2012). "Effects of regular aspirin on long-term cancer incidence and metastasis: A systematic comparison of evidence from observational studies versus randomised trials". The Lancet Oncology. 13 (5): 518–27. doi:10.1016/S1470-2045(12)70112-2. PMID 22440112.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  7. Rothwell, Peter M; Price, Jacqueline F; Fowkes, F Gerald R; Zanchetti, Alberto; Roncaglioni, Maria Carla; Tognoni, Gianni; Lee, Robert; Belch, Jill FF; Wilson, Michelle; et al. (2012). "Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the time course of risks and benefits in 51 randomised controlled trials". The Lancet. 379 (9826): 1602–1612. doi:10.1016/S0140-6736(11)61720-0.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  8. Rothwell, Peter M; Wilson, Michelle; Price, Jacqueline F; Belch, Jill FF; Meade, Tom W; Mehta, Ziyah (2012). "Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials". The Lancet. 379 (9826): 1591–1601. doi:10.1016/S0140-6736(12)60209-8. PMID 22440947.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  9. "Daily aspirin therapy: Understand the benefits and risks". Mayo Clinic. Retrieved 21 March 2015.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  10. 10.0 10.1 10.2 Macdonald S (2002). "Aspirin use to be banned in under 16-year olds". BMJ. 325 (7371): 988c–988. doi:10.1136/bmj.325.7371.988/c. PMC 1169585. PMID 12411346.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  11. Burke, Anne; Smyth, Emer; FitzGerald, Garret A. (2006). "26: Analgesic Antipyretic and Antiinflammatory Agents". In Brunton, Laurence L.; Lazo, John S.; Parker, Keith (eds.). Goodman & Gilman's The Pharmacological Basis of Therapeutics (11 ed.). New York: McGraw-Hill. pp. 671–716. ISBN 978-0-07-142280-2.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  13. Stone Edmund (1763). "An Account of the Success of the Bark of the Willow in the Cure of Agues. In a Letter to the Right Honourable George Earl of Macclesfield, President of R. S. from the Rev. Mr. Edmund Stone, of Chipping-Norton in Oxfordshire". Philosophical Transactions of the Royal Society of London. 53: 195–200. doi:10.1098/rstl.1763.0033. JSTOR 105721.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  14. 14.0 14.1 Sneader, W. (2000). "The discovery of aspirin: A reappraisal". BMJ (Clinical research ed.). 321 (7276): 1591–1594. doi:10.1136/bmj.321.7276.1591. PMC 1119266. PMID 11124191.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  15. Schrör, Karsten (2009). Acetylsalicylic acid. Wiley. ISBN 978-3-527-32109-4.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  16. 16.0 16.1 Warner, T. D.; Warner TD, Mitchell JA (2002). "Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?". Proceedings of the National Academy of Sciences of the United States of America. 99 (21): 13371–3. doi:10.1073/pnas.222543099. PMC 129677. PMID 12374850.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  17. "The use of aspirin". Retrieved 11 May 2011.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  18. "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  19. 19.0 19.1 "Aspirin". The American Society of Health-System Pharmacists. Retrieved 3 April 2011.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  20. "Aspirin for Reducing Your Risk of Heart Attack and Stroke: Know the Facts". U.S. Food and Drug Administration. Retrieved 26 July 2012.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  21. "Aspirin for the Prevention of Cardiovascular Disease". U.S. Preventive Services Task Force. Retrieved 26 July 2012.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  22. Seshasai, SR; Wijesuriya, S; Sivakumaran, R; Nethercott, S; Erqou, S; Sattar, N; Ray, KK (13 February 2012). "Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials". Archives of Internal Medicine. 172 (3): 209–16. doi:10.1001/archinternmed.2011.628. PMID 22231610.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  23. 23.0 23.1 Algra, AM; Rothwell, PM (May 2012). "Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials". The lancet oncology. 13 (5): 518–27. doi:10.1016/S1470-2045(12)70112-2. PMID 22440112.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  24. Sachs, C. J. (2005). "Oral analgesics for acute nonspecific pain". American family physician. 71 (5): 913–918. PMID 15768621.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  25. Gaciong (2003). "The real dimension of analgesic activity of aspirin". Thrombosis Research. 110 (5–6): 361–364. doi:10.1016/j.thromres.2003.08.009. PMID 14592563.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  26. Derry, C. J.; Derry, S.; Moore, R. A. (2012). Derry, Sheena (ed.). "Caffeine as an analgesic adjuvant for acute pain in adults". Cochrane database of systematic reviews (Online). 3: CD009281. doi:10.1002/14651858.CD009281.pub2. PMID 22419343.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  27. "BLOWFISH (aspirin, caffeine) tablet, effervescent [Rally Labs LLC]". DailyMed. U.S. Federal Drug Administration. Retrieved 27 July 2012.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  28. Hersh, E.; Moore, P.; Ross, G. (2000). "Over-the-counter analgesics and antipyretics: A critical assessment". Clinical Therapeutics. 22 (5): 500–548. doi:10.1016/S0149-2918(00)80043-0. PMID 10868553.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  29. Mett, A.; Tfelt-Hansen, P. (2008). "Acute migraine therapy: Recent evidence from randomized comparative trials". Current Opinion in Neurology. 21 (3): 331–337. doi:10.1097/WCO.0b013e3282fee843. PMID 18451718.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  30. Kingery, WS (November 1997). "A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes". Pain. 73 (2): 123–39. doi:10.1016/S0304-3959(97)00049-3. PMID 9415498.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  31. Loder, E; Rizzoli, P (12 January 2008). "Tension-type headache". BMJ (Clinical research ed.). 336 (7635): 88–92. doi:10.1136/bmj.39412.705868.AD. PMC 2190284. PMID 18187725.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  32. Gilmore, B; Michael, M (1 February 2011). "Treatment of acute migraine headache". American family physician. 83 (3): 271–80. PMID 21302868.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  33. Bartfai, T; Conti, B (16 March 2010). "Fever". TheScientificWorldJournal. 10: 490–503. doi:10.1100/tsw.2010.50. PMC 2850202. PMID 20305990.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  34. Pugliese, A; Beltramo, T; Torre, D (October 2008). "Reye's and Reye's-like syndromes". Cell biochemistry and function. 26 (7): 741–6. doi:10.1002/cbf.1465. PMID 18711704.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  35. Beutler, AI; Chesnut, GT; Mattingly, JC; Jamieson, B (15 December 2009). "FPIN's Clinical Inquiries. Aspirin use in children for fever or viral syndromes". American family physician. 80 (12): 1472. PMID 20000310.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  36. "Medications Used to Treat Fever". American Academy of Pediatrics. Retrieved 25 November 2012.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  37. "51 FR 8180" (PDF). United States Federal Register. 51 (45). 7 March 1986. Retrieved 25 November 2012.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  38. Thea Morris, Melanie Stables, Adrian Hobbs, Patricia de Souza, Paul Colville-Nash, Tim Warner, Justine Newson, Geoffrey Bellingan, and Derek W. Gilroy, "Effects of Low-Dose Aspirin on Acute Inflammatory Responses in Humans", J. Immunology, 183: 2089-2096, 2009 (accessed Aug 29, 2014)
  39. "Myocardial Infarction with ST-Segment Elevation: The Acute Management of Myocardial Infarction with ST-Segment Elevation [Internet]. NICE Clinical Guidelines, No. 167". July 2013: 17.2. Cite journal requires |journal= (help)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  40. 40.0 40.1 Quaas, Joshua (28 November 2009). "Aspirin Given Immediately for a Major Heart Attack (STEMI)". Retrieved 15 October 2015.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  41. Newman, David (10 July 2011). "Aspirin to Prevent Cardiovascular Disease in Patients with Known Heart Disease or Strokes". NNT. Retrieved 30 November 2015.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  42. Hall, SL; Lorenc, T (1 February 2010). "Secondary prevention of coronary artery disease". American family physician. 81 (3): 289–96. PMID 20112887.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  43. Baigent, C; Blackwell, L; Collins, R; Emberson, J; Godwin, J; Peto, R; Buring, J; Hennekens, C; Kearney, P; Meade, T; Patrono, C; Roncaglioni, MC; Zanchetti, A (2009). "Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials". Lancet. 373 (9678): 1849–60. doi:10.1016/S0140-6736(09)60503-1. PMC 2715005. PMID 19482214.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  44. Antithrombotic Trialists' (ATT), Collaboration; Baigent, C; Blackwell, L; Collins, R; Emberson, J; Godwin, J; Peto, R; Buring, J; Hennekens, C; Kearney, P; Meade, T; Patrono, C; Roncaglioni, MC; Zanchetti, A (30 May 2009). "Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials". Lancet (London, England). 373 (9678): 1849–60. doi:10.1016/s0140-6736(09)60503-1. PMC 2715005. PMID 19482214.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  45. Newman, David (8 January 2015). "Aspirin to Prevent a First Heart Attack or Stroke". theNNT. Retrieved 30 November 2015.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  46. Wolff, T; Miller, T; Ko, S (17 March 2009). "Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force". Annals of Internal Medicine. 150 (6): 405–10. doi:10.7326/0003-4819-150-6-200903170-00009. PMID 19293073.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  47. U.S. Preventive Services Task Force. "Aspirin for the Prevention of Cardiovascular Disease: Recommendation Statement". Retrieved 15 August 2012.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  48. Berger, JS; Lala, A, Krantz, MJ, Baker, GS, Hiatt, WR (July 2011). "Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials". American heart journal. 162 (1): 115–24.e2. doi:10.1016/j.ahj.2011.04.006. PMID 21742097.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  49. Norris, JW (September 2005). "Antiplatelet agents in secondary prevention of stroke: a perspective". Stroke; a journal of cerebral circulation. 36 (9): 2034–6. doi:10.1161/01.STR.0000177887.14339.46. PMID 16100022.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  50. Sleight, P; Pouleur, H; Zannad, F (July 2006). "Benefits, challenges, and registerability of the polypill". European heart journal. 27 (14): 1651–6. doi:10.1093/eurheartj/ehi841. PMID 16603580.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  51. Wang, TH; Bhatt, DL; Topol, EJ (March 2006). "Aspirin and clopidogrel resistance: an emerging clinical entity". European heart journal. 27 (6): 647–54. doi:10.1093/eurheartj/ehi684. PMID 16364973.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  52. Oliveira, DC; Silva, RF; Silva, DJ; Lima, VC (September 2010). "Aspirin resistance: fact or fiction?". Arquivos brasileiros de cardiologia. 95 (3): e91–4. doi:10.1590/S0066-782X2010001300024. PMID 20944898.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  53. Topçuoglu, MA; Arsava, EM; Ay, H (February 2011). "Antiplatelet resistance in stroke". Expert Review of Neurotherapeutics. 11 (2): 251–63. doi:10.1586/ern.10.203. PMC 3086673. PMID 21306212.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  54. Ben-Dor, I; Kleiman, NS; Lev, E (15 July 2009). "Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy". The American journal of cardiology. 104 (2): 227–33. doi:10.1016/j.amjcard.2009.03.022. PMID 19576352.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  55. National Guideline Clearinghouse (NGC). "2011 ACCF/AHA/SCAI guideline for percutaneous coronary artery intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions". United States Agency for Healthcare Research and Quality (AHRQ). Retrieved 28 August 2012.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  56. Musumeci, G; Di Lorenzo, E; Valgimigli, M (December 2011). "Dual antiplatelet therapy duration: what are the drivers?". Current Opinion in Cardiology. 26 Suppl 1: S4–14. doi:10.1097/ PMID 22129582.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  57. 57.0 57.1 Cuzick, J; Thorat, MA; Bosetti, C; Brown, PH; Burn, J; Cook, NR; Ford, LG; Jacobs, EJ; Jankowski, JA; La Vecchia, C; Law, M; Meyskens, F; Rothwell, PM; Senn, HJ; Umar, A (5 August 2014). "Estimates of benefits and harms of prophylactic use of aspirin in the general population". Annals of Oncology. 26: 47–57. doi:10.1093/annonc/mdu225. PMID 25096604.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  58. Manzano, A; Pérez-Segura, P (2012). "Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention?". TheScientificWorldJournal. 2012: 327341. doi:10.1100/2012/327341. PMC 3353298. PMID 22649288.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  59. Chan, AT; Arber, N; Burn, J; Chia, WK; Elwood, P; Hull, MA; Logan, RF; Rothwell, PM; Schrör, K; Baron, JA (February 2012). "Aspirin in the chemoprevention of colorectal neoplasia: an overview". Cancer prevention research (Philadelphia, Pa.). 5 (2): 164–78. doi:10.1158/1940-6207.CAPR-11-0391. PMC 3273592. PMID 22084361.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  60. Thun, MJ; Jacobs, EJ; Patrono, C (3 April 2012). "The role of aspirin in cancer prevention". Nature Reviews Clinical Oncology. 9 (5): 259–67. doi:10.1038/nrclinonc.2011.199. PMID 22473097.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  61. Sutcliffe, P; Connock, M; Gurung, T; Freeman, K; Johnson, S; Kandala, NB; Grove, A; Gurung, B; Morrow, S; Clarke, A (September 2013). "Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews". Health technology assessment (Winchester, England). 17 (43): 1–253. doi:10.3310/hta17430. PMID 24074752.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  62. Kim, SE (2014). "The benefit-risk consideration in long-term use of alternate-day, low dose aspirin: focus on colorectal cancer prevention". Annals of Gastroenterology. 27 (1): 87–88. PMID 24714632.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  63. U.S. Preventive Services Task, Force (6 March 2007). "Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement". Annals of Internal Medicine. 146 (5): 361–4. doi:10.7326/0003-4819-146-5-200703060-00008. PMID 17339621.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  64. 64.0 64.1 National Heart Foundation of Australia (RF/RHD guideline development working group) and the Cardiac Society of Australia and New Zealand (2006). "Diagnosis and management of acute rheumatic fever and rheumatic heart disease in Australia. An evidence-based review" (PDF). National Heart Foundation of Australia. pp. 33–37. Archived from the original (PDF) on 26 July 2008. Retrieved 9 May 2011.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  65. Working Group on Pediatric Acute Rheumatic Fever and Cardiology Chapter of Indian Academy of, Pediatrics; Saxena, A; Kumar, RK; Gera, RP; Radhakrishnan, S; Mishra, S; Ahmed, Z (July 2008). "Consensus guidelines on pediatric acute rheumatic fever and rheumatic heart disease". Indian pediatrics. 45 (7): 565–73. PMID 18695275.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  66. Hashkes; Tauber, T.; Somekh, E.; Brik, R.; Barash, J.; Mukamel, M.; Harel, L.; Lorber, A.; Berkovitch, M.; Uziel, Y.; Pediatric Rheumatlogy Study Group of Israel (2003). "Naproxen as an alternative to aspirin for the treatment of arthritis of rheumatic fever: a randomized trial". The Journal of pediatrics. 143 (3): 399–401. doi:10.1067/S0022-3476(03)00388-3. PMID 14517527.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  67. Rowley, AH; Shulman, ST (February 2010). "Pathogenesis and management of Kawasaki disease". Expert review of anti-infective therapy. 8 (2): 197–203. doi:10.1586/eri.09.109. PMC 2845298. PMID 20109049.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  68. Baumer, JH; Love, SJ; Gupta, A; Haines, LC; Maconochie, I; Dua, JS (18 October 2006). Baumer, J Harry (ed.). "Salicylate for the treatment of Kawasaki disease in children". Cochrane Database of Systematic Reviews (4): CD004175. doi:10.1002/14651858.CD004175.pub2. PMID 17054199.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  69. Duley, L.; Henderson-Smart, D. J.; Meher, S.; King, J. F. (2007). Duley, Lelia (ed.). "Antiplatelet agents for preventing pre-eclampsia and its complications". Cochrane database of systematic reviews (Online) (2): CD004659. doi:10.1002/14651858.CD004659.pub2. PMID 17443552.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  70. Roberge, S. P.; Villa, P.; Nicolaides, K.; Giguère, Y.; Vainio, M.; Bakthi, A.; Ebrashy, A.; Bujold, E. (2012). "Early Administration of Low-Dose Aspirin for the Prevention of Preterm and Term Preeclampsia: A Systematic Review and Meta-Analysis". Fetal Diagnosis and Therapy. 31 (3): 141–146. doi:10.1159/000336662. PMID 22441437.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  71. Dorsch MP, Lee JS, Lynch DR, Dunn SP, Rodgers JE, Schwartz T, Colby E, Montague D, Smyth SS (2007). "Aspirin Resistance in Patients with Stable Coronary Artery Disease with and without a History of Myocardial Infarction". Annals of Pharmacotherapy. 41 (May): 737–41. doi:10.1345/aph.1H621. PMID 17456544.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  72. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR (2008). "Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis". BMJ. 336 (7637): 195–8. doi:10.1136/bmj.39430.529549.BE. PMC 2213873. PMID 18202034.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  73. Pignatelli P, Di Santo S, Barillà F, Gaudio C, Violi F (2008). "Multiple anti-atherosclerotic treatments impair aspirin compliance: effects on aspirin resistance". J. Thromb. Haemost. 6 (10): 1832–4. doi:10.1111/j.1538-7836.2008.03122.x. PMID 18680540.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  74. Tilo Grosser, Susanne Fries, John A. Lawson, Shiv C. Kapoor, Gregory R. Grant and Garret A. FitzGerald (2013). "Drug Resistance and Pseudoresistance: An Unintended Consequence of Enteric Coating Aspirin". Circulation (published 4 December 2012). 127 (3): 377–85. doi:10.1161/CIRCULATIONAHA.112.117283. PMC 3552520. PMID 23212718. Unknown parameter |laysummary= ignored (help)CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  75. "Invention of the Safety Cap". Retrieved 4 September 2015.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  76. 76.0 76.1 British National Formulary (45 ed.). British Medical Journal and Royal Pharmaceutical Society of Great Britain. 2003.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  77. "Aspirin monograph: dosages, etc". Retrieved 11 May 2011.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  78. (USPSTF, March 2009)
  79. 79.0 79.1 79.2 "Aspirin: More Evidence That Low Dose Is All That Is Needed (from Medscape)". Retrieved 11 May 2011.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  80. British National Formulary for Children. British Medical Journal and Royal Pharmaceutical Society. 2006.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  81. 81.0 81.1 81.2 81.3 81.4 "Aspirin information from". Archived from the original on 9 May 2008. Retrieved 8 May 2008. Unknown parameter |deadurl= ignored (help)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  82. 82.0 82.1 82.2 "Oral Aspirin information". First DataBank. Archived from the original on 9 June 2008. Retrieved 8 May 2008. Unknown parameter |deadurl= ignored (help)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  83. Raithel, M.; Baenkler, H. W.; Naegel, A.; Buchwald, F.; Schultis, H. W.; Backhaus, B.; Kimpel, S.; Koch, H.; Mach, K.; Hahn, E. G.; Konturek, P. C. (2005). "Significance of salicylate intolerance in diseases of the lower gastrointestinal tract" (PDF). J. Physiol. Pharmacol. 56 Suppl 5: 89–102. PMID 16247191.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  84. Senna GE, Andri G, Dama AR, Mezzelani P, Andri L (1995). "Tolerability of imidazole salycilate in aspirin-sensitive patients". Allergy Proc. 16 (5): 251–4. doi:10.2500/108854195778702675. PMID 8566739.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  85. 85.0 85.1 "PDR Guide to Over the Counter (OTC) Drugs". Archived from the original on 10 April 2008. Retrieved 28 April 2008. Unknown parameter |deadurl= ignored (help)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  86. Livingstone, Frank B. (1985). Frequencies of hemoglobin variants: thalassemia, the glucose-6-phosphate dehydrogenase deficiency, G6PD variants, and ovalocytosis in human populations. Oxford University Press. ISBN 0-19-503634-4.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  87. "Dengue and Dengue Hemorrhagic Fever: Information for Health Care Practitioners". Archived from the original on 17 March 2008. Retrieved 28 April 2008.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  88. 88.0 88.1 88.2 Sørensen HT; Mellemkjaer L; Blot WJ; Nielsen, Gunnar Lauge; Steffensen, Flemming Hald; McLaughlin, Joseph K.; Olsen, Jorgen H. (2000). "Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin". Am. J. Gastroenterol. 95 (9): 2218–24. doi:10.1111/j.1572-0241.2000.02248.x. PMID 11007221.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  89. Delaney JA, Opatrny L, Brophy JM & Suissa S (2007). "Drug–drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding". CMAJ. 177 (4): 347–51. doi:10.1503/cmaj.070186. PMC 1942107. PMID 17698822.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  90. Wallace, J. L. (2008). "Prostaglandins, NSAIDs, and Gastric Mucosal Protection: Why Doesn't the Stomach Digest Itself?". Physiological Reviews. 88 (4): 1547–1565. doi:10.1152/physrev.00004.2008. PMID 18923189.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  91. Fiorucci, S.; Santucci, L.; Wallace, J. L.; Sardina, M.; Romano, M.; Del Soldato, P.; Morelli, A. (2003). "Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa". Proceedings of the National Academy of Sciences. 100 (19): 10937–10941. doi:10.1073/pnas.1933204100. PMC 196906. PMID 12960371.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  92. "General Chemistry Online: FAQ: Acids and bases: What is the buffer system in buffered aspirin?". Retrieved 11 May 2011.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  93. Dammann, H. G.; Saleki, M.; Torz, M.; Schulz, H. U.; Krupp, S.; Schürer, M.; Timm, J.; Gessner, U. (2004). "Effects of buffered and plain acetylsalicylic acid formulations with and without ascorbic acid on gastric mucosa in healthy subjects". Alimentary pharmacology & therapeutics. 19 (3): 367–374. doi:10.1111/j.1365-2036.2004.01742.x. PMID 14984384.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  94. Konturek; Kania, J; Hahn, EG; Konturek, JW (2006). "Ascorbic acid attenuates aspirin-induced gastric damage: role of inducible nitric oxide synthase". J Physiol Pharmacol. 57 Suppl 5 (5): 125–36. PMID 17218764.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  95. Guitton MJ, Caston J, Ruel J, Johnson RM, Pujol R, Puel JL (2003). "Salicylate induces tinnitus through activation of cochlear NMDA receptors". J. Neurosci. 23 (9): 3944–52. PMID 12736364.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  96. 96.0 96.1 Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB (1999). "Reye's syndrome in the United States from 1981 through 1997". N. Engl. J. Med. 340 (18): 1377–82. doi:10.1056/NEJM199905063401801. PMID 10228187.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  97. Reye's syndrome.
  98. Stadelmann, WK; Digenis, AG; Tobin, GR (August 1998). "Impediments to wound healing". American journal of surgery. 176 (2A Suppl): 39S–47S. PMID 9777971.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  99. Maessen-Visch, MB; de Roos, KP (19 May 2014). "Dutch Venous Ulcer guideline update". Phlebology / Venous Forum of the Royal Society of Medicine. 29 (1 suppl): 153–156. doi:10.1177/0268355514529693. PMID 24843102.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  100. Berges-Gimeno MP & Stevenson DD (2004). "Nonsteroidal anti-inflammatory drug-induced reactions and desensitization". J Asthma. 41 (4): 375–84. doi:10.1081/JAS-120037650. PMID 15281324.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  101. Vernooij MW, Haag MD, der Lugt A, Hofman A, Krestin GP, Stricker BH, Breteler MM (2009). "Use of antithrombotic drugs and the presence of cerebral microbleeds: the Rotterdam Scan Study". Arch Neurol. 66 (6): 714–20. doi:10.1001/archneurol.2009.42. PMID 19364926.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  102. Gorelick PB (2009). "Cerebral microbleeds: evidence of heightened risk associated with aspirin use". Arch Neurol. 66 (6): 691–3. doi:10.1001/archneurol.2009.85. PMID 19506128.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  103. 103.0 103.1 He, J.; Whelton, P. K.; Vu, B.; Klag, M. J. (1998). "Aspirin and risk of hemorrhagic stroke: A meta-analysis of randomized controlled trials". JAMA: the Journal of the American Medical Association. 280 (22): 1930–1935. doi:10.1001/jama.280.22.1930. PMID 9851479.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  104. Saloheimo, P.; Ahonen, M.; Juvela, S.; Pyhtinen, J.; Savolainen, E. R.; Hillbom, M. (2005). "Regular Aspirin-Use Preceding the Onset of Primary Intracerebral Hemorrhage is an Independent Predictor for Death". Stroke. 37 (1): 129–133. doi:10.1161/01.STR.0000196991.03618.31. PMID 16322483.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  105. Medical knowledge self-assessment program for students 4, By American College of Physicians, Clerkship Directors in Internal Medicine, Nephrology 227, Item 29
  106. Scher, K.S. (1996). "Unplanned reoperation for bleeding". Am Surg. 62 (1): 52–55. PMID 8540646.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  107. Staff (9 July 2015). "FDA Strengthens Warning of Heart Attack and Stroke Risk for Non-Steroidal Anti-Inflammatory Drugs". FDA. Retrieved 9 July 2015.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  108. Kreplick, LW. (2001). "Salicylate Toxicity in Emergency Medicine". Medscape.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  109. Gaudreault P, Temple AR, Lovejoy FH Jr (1982). "The relative severity of acute versus chronic salicylate poisoning in children: a clinical comparison". Pediatrics. 70 (4): 566–9. PMID 7122154.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles> (primary source)
  110. Marx, John (2006). Rosen's emergency medicine: concepts and clinical practice. Mosby/Elsevier. p. 2242. ISBN 978-0-323-02845-5.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  111. Morra P, Bartle WR, Walker SE, Lee SN, Bowles SK, Reeves RA (1996). "Serum concentrations of salicylic acid following topically applied salicylate derivatives". Ann. Pharmacother. 30 (9): 935–40. PMID 8876850.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  112. R. Baselt (2011). Disposition of Toxic Drugs and Chemicals in Man (9th ed.). Seal Beach, California: Biomedical Publications. pp. 20–23.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  113. "Information for Healthcare Professionals: Concomitant Use of Ibuprofen and Aspirin". FDA. U.S. Department of Health & Human Services. September 2006. Archived from the original on 13 November 2010. Retrieved 22 November 2010. Unknown parameter |deadurl= ignored (help)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  114. Katzung (1998), Basic and Clinical Pharmacology, McGraw-Hill, p. 584.
  115. Loh HS, Watters K & Wilson CW (1 November 1973). "The Effects of Aspirin on the Metabolic Availability of Ascorbic Acid in Human Beings". J Clin Pharmacol. 13 (11): 480–6. doi:10.1002/j.1552-4604.1973.tb00203.x. PMID 4490672.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  116. Basu TK (1982). "Vitamin C-aspirin interactions". Int J Vitam Nutr Res Suppl. 23: 83–90. PMID 6811490.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  117. Ioannides C, Stone AN, Breacker PJ & Basu TK (1982). "Impairment of absorption of ascorbic acid following ingestion of aspirin in guinea pigs". Biochem Pharmacol. 31 (24): 4035–8. doi:10.1016/0006-2952(82)90652-9. PMID 6818974.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  118. EF Reynolds, ed. (1982). "Aspirin and similar analgesic and anti-inflammatory agents". Martindale: The Extra Pharmacopoeia (28th ed.). pp. 234–82.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  119. "Acetylsalicylic acid". Pocket Guide to Chemical Hazards. NIOSH. 13 February 2015.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  120. "Appendix G: 1989 Air Contaminants Update Project - Exposure Limits NOT in Effect". NIOSH Pocket Guide to Chemical Hazards. NIOSH. 13 February 2015.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  121. Richard Leroy Myers (30 August 2007). The 100 Most Important Chemical Compounds: A Reference Guide. ABC-CLIO. p. 10. ISBN 978-0-313-33758-1. Retrieved 18 November 2012.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  122. "Acetylsalicylic acid". Jinno Laboratory, School of Materials Science, Toyohashi University of Technology. 4 March 1996. Archived from the original on 20 January 2012. Retrieved 12 April 2014.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  123. Palleros, Daniel R. (2000). Experimental Organic Chemistry. New York: John Wiley & Sons. p. 494. ISBN 0-471-28250-2.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  124. Barrans, Richard. "Aspirin Aging". Newton BBS. Archived from the original on 18 May 2008. Retrieved 8 May 2008. Unknown parameter |deadurl= ignored (help)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  125. Carstensen, J.T.; F Attarchi and XP Hou (1985). "Decomposition of aspirin in the solid state in the presence of limited amounts of moisture". Journal of Pharmaceutical Sciences. 77 (4): 318–21. doi:10.1002/jps.2600770407. PMID 4032246.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  126. Vishweshwar, P.; McMahon, J. A.; Oliveira, M.; Peterson, M. L.; Zaworotko, M. J. (2005). "The Predictably Elusive Form II of Aspirin". Journal of the American Chemical Society. 127 (48): 16802–16803. doi:10.1021/ja056455b. PMID 16316223.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  127. Bond, Andrew D.; Boese, Roland; and Desiraju, Gautam R. (2007). "On the Polymorphism of Aspirin: Crystalline Aspirin as Intergrowths of Two "Polymorphic" Domains". Angewandte Chemie International Edition. 46 (4): 618–622. doi:10.1002/anie.200603373. PMID 17139692.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  128. Vane, John Robert (1971). "Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs". Nature – New Biology. 231 (25): 232–5. doi:10.1038/newbio231232a0. PMID 5284360.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  129. Vane JR, Botting RM; Botting (2003). "The mechanism of action of aspirin" (PDF). Thromb Res. 110 (5–6): 255–8. doi:10.1016/S0049-3848(03)00379-7. PMID 14592543.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  130. "The Nobel Prize in Physiology or Medicine 1982". Nobelprize.or.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  131. "Aspirin in Heart Attack and Stroke Prevention". American Heart Association. Archived from the original on 31 March 2008. Retrieved 8 May 2008.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  132. Tohgi, H; S Konno, K Tamura, B Kimura and K Kawano (1992). "Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin". Stroke. 23 (10): 1400–1403. doi:10.1161/01.STR.23.10.1400. PMID 1412574.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  133. Achhrish goel, Ruchi gupta Anubhav goswami Madhu soodan sharma Yogesh sharma (2011). "Pharmacokinetic Solubility And Dissolution Profile of Non-Steroidal Anti-Inflammatory Drugs". 2 (3). Cite journal requires |journal= (help)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  134. Martínez-González J, Badimon L; Badimon (2007). "Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks". Curr Pharm Des. 13 (22): 2215–27. doi:10.2174/138161207781368774. PMID 17691994.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  135. Funk CD, FitzGerald GA; Fitzgerald (November 2007). "COX-2 inhibitors and cardiovascular risk". J Cardiovasc Pharmacol. 50 (5): 470–9. doi:10.1097/FJC.0b013e318157f72d. PMID 18030055.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  136. Somasundaram; Sigthorsson, G; Simpson, RJ; Watts, J; Jacob, M; Tavares, IA; Rafi, S; Roseth, A; Foster, R; et al. (2000). "Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat". Aliment Pharmacol Ther. 14 (5): 639–650. doi:10.1046/j.1365-2036.2000.00723.x. PMID 10792129.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  137. Paul-Clark, Mark J.; Cao, Thong van; Moradi-Bidhendi, Niloufar; Cooper, Dianne & Gilroy, Derek W. (2004). "15-epi-lipoxin A4–mediated Induction of Nitric Oxide Explains How Aspirin Inhibits Acute Inflammation". J. Exp. Med. 200 (1): 69–78. doi:10.1084/jem.20040566. PMC 2213311. PMID 15238606.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  138. McCarty, M. F.; Block, K. I. (2006). "Preadministration of high-dose salicylates, suppressors of NF-kappaB activation, may increase the chemosensitivity of many cancers: an example of proapoptotic signal modulation therapy". Integr Cancer Ther. 5 (3): 252–268. doi:10.1177/1534735406291499. PMID 16880431.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  139. Hawley, S. A.; Fullerton, M. D.; Ross, F. A.; Schertzer, J. D.; Chevtzoff, C.; Walker, K. J.; Peggie, M. W.; Zibrova, D.; Green, K. A.; Mustard, K. J.; Kemp, B. E.; Sakamoto, K.; Steinberg, G. R.; Hardie, D. G. (2012). "The Ancient Drug Salicylate Directly Activates AMP-Activated Protein Kinase". Science. 336 (6083): 918–922. doi:10.1126/science.1215327. PMC 3399766. PMID 22517326.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  140. Raffensperger, Lisa (19 April 2012). "Clues to aspirin's anti-cancer effects revealed". New Scientist. 214 (2862): 16. doi:10.1016/S0262-4079(12)61073-2.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  141. Bhat (2009). "Aspirin inhibits camptothecin-induced p21CIP1 levels and potentiates apoptosis in human breast cancer cells". International Journal of Oncology. 34 (3). doi:10.3892/ijo_00000185.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  142. Bhat (2009). "Does aspirin acetylate multiple cellular proteins? (Review)". Molecular Medicine Reports. 2 (4). doi:10.3892/mmr_00000132.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  143. Ferguson, RK; Boutros, AR (17 August 1970). "Death following self-poisoning with aspirin". Journal of the American Medical Association. 213 (7): 1186–8. doi:10.1001/jama.213.7.1186. PMID 5468267.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  144. Kaufman, FL; Dubansky, AS (April 1970). "Darvon poisoning with delayed salicylism: a case report". Pediatrics. 49 (4): 610–1. PMID 5013423.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  145. 145.0 145.1 145.2 Levy, G; Tsuchiya, T (31 August 1972). "Salicylate accumulation kinetics in man". New England Journal of Medicine. 287 (9): 430–2. doi:10.1056/NEJM197208312870903. PMID 5044917.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  146. 2,3-Dihydroxybenzoic acid is a product of human aspirin metabolism. Martin Grootveld and Barry Halliwell, Biochemical Pharmacology, Volume 37, Issue 2, 15 January 1988, pages 271–280, doi:10.1016/0006-2952(88)90729-0
  147. Hartwig, Otto H (14 November 1983). "Pharmacokinetic considerations of common analgesics and antipyretics". American Journal of Medicine. 75 (5A): 30–7. doi:10.1016/0002-9343(83)90230-9. PMID 6606362.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  148. Done, AK (November 1960). "Salicylate intoxication. Significance of measurements of salicylate in blood in cases of acute ingestion". Pediatrics. 26: 800–7. PMID 13723722.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  149. Chyka PA, Erdman AR, Christianson G, Wax PM, Booze LL, Manoguerra AS, Caravati EM, Nelson LS, Olson KR, Cobaugh DJ, Scharman EJ, Woolf AD, Troutman WG; Americal Association of Poison Control Centers; Healthcare Systems Bureau, Health Resources and Services Administration, Department of Health and Human Services. (2007). "Salicylate poisoning: an evidence-based consensus guideline for out-of-hospital management". Clin Toxicol (Phila). 45 (2): 95–131. doi:10.1080/15563650600907140. PMID 17364628.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  150. Prescott LF, Balali-Mood M, Critchley JA, Johnstone AF, Proudfoot AT; Balali-Mood; Critchley; Johnstone; Proudfoot (1982). "Diuresis or urinary alkalinisation for salicylate poisoning?". Br Med J (Clin Res Ed). 285 (6352): 1383–6. doi:10.1136/bmj.285.6352.1383. PMC 1500395. PMID 6291695.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  151. Dargan PI, Wallace CI, Jones AL.; Wallace; Jones (2002). "An evidenced based flowchart to guide the management of acute salicylate (aspirin) overdose". Emerg Med J. 19 (3): 206–9. doi:10.1136/emj.19.3.206. PMC 1725844. PMID 11971828.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  152. Mary Bellis (16 June 2010). "History of aspirin". Retrieved 11 May 2011.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  153. Gerhardt, Ch. (1853). "Untersuchungen über die wasserfreien organischen Säuren". Annalen der Chemie und Pharmacie (in Deutsch). 87: 149–179. doi:10.1002/jlac.18530870107. Unknown parameter |trans_title= ignored (help)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles> See especially pages 162-163.
  154. von Gilm H (1859). "Acetylderivate der Phloretin- und Salicylsäure". Annalen der Chemie und Pharmacie (in Deutsch). 112 (2): 180–182. doi:10.1002/jlac.18591120207. Unknown parameter |trans_title= ignored (help)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  155. Schröder, Prinzhorn, Kraut K; Prinzhorn; Kraut (1869). "Ueber Salicylverbindungen". Annalen der Chemie und Pharmacie (in Deutsch). 150 (1): 1–20. doi:10.1002/jlac.18691500102. Unknown parameter |trans_title= ignored (help)CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>See especially pages 9-13; the structural formula of acetylsalicylic acid appears on p. 12.
  156. Mahdi, JG; Mahdi, AJ, Mahdi, AJ, Bowen, ID (April 2006). "The historical analysis of aspirin discovery, its relation to the willow tree and antiproliferative and anticancer potential". Cell proliferation. 39 (2): 147–55. doi:10.1111/j.1365-2184.2006.00377.x. PMID 16542349.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  157. Singer, H. (1901). "Ueber Aspirin". Pflügers Archiv: European Journal of Physiology. 84 (11–12): 527–546. doi:10.1007/BF01769129.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  158. Jeffreys 2005, pp. 73
  159. Starko, Karen M. (2009). "Salicylates and Pandemic Influenza Mortality, 1918–1919 Pharmacology, Pathology, and Historic Evidence". Clinical Infectious Diseases. 49 (9): 1405–1410. doi:10.1086/606060. PMID 19788357.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  160. Jeffreys 2005, pp. 136–142, 151–152
  161. "Bayer patents aspirin – This Day in History – 3/6/1899". Retrieved 11 May 2011.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  162. Jeffreys 2005, pp. 212–217
  163. Jeffreys 2005, pp. 226–231
  164. Jeffreys 2005, pp. 267–269
  166. "Research Confirms and Points to Future Aspirin Uses For Disease Prevention – re> BERLIN, Dec. 1 /PRNewswire/". Retrieved 5 May 2014.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  167. Bayer Co. v. United Drug Co., 272 F. 505, p.512 (S.D.N.Y 1921) (“Disregarding this, however, it was too late in the autumn of 1915 to reclaim the word which had already passed into the public domain. If the consuming public had once learned to know 'Aspirin' as the accepted name for the drug, perhaps it is true that an extended course of education might have added to it some proprietary meaning, but it would be very difficult to prove that it had been done in 17 months, and in any case the plaintiff does not try to prove it. [...] Yet, had it not been indifferent to the results of selling to the consumer, it could have protected itself just as well at the time when consumers began to buy directly as in 1915. Nothing would have been easier than to insist that the tablet makers should market the drug in small tin boxes bearing the plaintiff's name, or to take over the sale just as it did later. Instead of this, they allowed the manufacturing chemists to build up this part of the demand without regard to the trade-mark. Having made that bed, they must be content to lie in it. Hence it appears to me that nothing happening between October, 1915, and March, 1917, will serve to turn the word into a trade-mark.”).
  168. CBE Style Manual Committee; Huth, Edward J. (1994). Scientific Style and Format: The CBE Manual for Authors, Editors, and Publishers. Cambridge University Press. p. 164. ISBN 978-0-521-47154-1.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  169. "Aspirin: the versatile drug". CBC News. 28 May 2009.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  170. Cheng, Tsung O. (2007). "The History of Aspirin". Texas Heart Institute Journal. 34 (3): 392–393. PMC 1995051. PMID 17948100.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  171. Sigma Aldrich. "Aspirin". Retrieved 13 July 2009.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>[dead link]
  172. British Pharmacopoeia. "Index BP 2009" (PDF). Retrieved 13 July 2009.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  173. Crosby, Janet Tobiassen (2006). "Veterinary Questions and Answers". Archived from the original on 8 September 2007. Retrieved 5 September 2007. Unknown parameter |deadurl= ignored (help)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  174. Cambridge H, Lees P, Hooke RE, Russell CS; Lees; Hooke; Russell (1991). "Antithrombotic actions of aspirin in the horse". Equine Vet J. 23 (2): 123–7. doi:10.1111/j.2042-3306.1991.tb02736.x. PMID 1904347.CS1 maint: multiple names: authors list (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  175. Lappin, Michael R., ed. (2001). Feline internal medicine secrets. Philadelphia: Hanley & Belfus. p. 160. ISBN 1-56053-461-3.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>

Further reading

  • Jeffreys, Diarmuid (11 August 2005). Aspirin: The Remarkable Story of a Wonder Drug. Bloomsbury USA. ISBN 1-58234-600-3.CS1 maint: ref=harv (link)<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>

External links